艾昆纬-放射配体治疗是新加坡癌症治疗的未来（英）

White PaperRadioligand Therapy as the Future of Cancer Care in SingaporeAUGUST 2025LUKE WILLBOURN, Principal, Strategy Consulting, IQVIASMITHA SREEDHARAN, Associate Director, Medical Writing, IQVIASTEVEN SURJA, Consultant, Strategy Consulting, IQVIAADIVITIYA BIHAGARA, Medical Writer 2, RWE Medical and Scientific Writing, IQVIATable of contentsOverview 1Executive summary 2Value of radioligand therapy 3Current status of PSMA+ mCRPC in Singapore 4Current landscape of RLT in Singapore — assessment of readiness and identified gaps 6Stakeholder awareness 6Clinical research on RLT 6Infrastructure for RLT 8Regulatory framework for RLT 10Funding scheme for RLT 12Potential solutions — case studies from different countries 13A call to action 15References 18About the authors 22About the contributors and observers 23 iqvia.com | 1Prostate cancer (PC) represents a significant and growing public health concern in Singapore, currently ranking as the most commonly diagnosed cancer among males. The burden of disease is expected to grow substantially in the coming years, driven by demographic aging and shifting lifestyle-related risk factors.Amid this growing burden, nuclear medicine is transforming cancer care by enabling precise diagnostics and targeted therapies. Radioligand Therapy (RLT), particularly Lutetium-177 (Lu-177)-based prostate-specific membrane antigen (PSMA)-targeted agents, has emerged as a promising and transformative approach in the management of metastatic Castration-Resistant Prostate Cancer (mCRPC).Nationally, PC prevalence is projected to reach 18,000 cases by 2040. A considerable proportion of these will progress to advanced stages, including mCRPC, for which conventional treatment options remain limited and patient outcomes often suboptimal.Nuclear medicine is transforming cancer care by allowing precise diagnostics and targeted therapies. Radioligand Therapy (RLT), particularly lutetium-177 (Lu-177)–based prostate-specific membrane antigen (PSMA)-targeted agents, has emerged as a transformative approach in the management of mCRPC. Several clinical trials such as VISION and PSMAfore have demonstrated that RLT is superior to Standard of Care (SoC), which includes Androgen Receptor Pathway Inhibitors (ARPIs) and taxane-based chemotherapies, in prolonging Progression-Free Survival (PFS) and improving Quality of Life (QoL). To fully realize the therapeutic potential of RLT in Singapore’s oncology landscape, there are valuable opportunities to boost stakeholder awareness, strengthen infrastructure, streamline regulatory processes, and enhance financing support.This white paper provides a comprehensive assessment of Singapore’s readiness to scale RLT as a standard-of-care treatment. It identifies critical gaps in stakeholder education, diagnostic and treatment capacity, workforce availability, and regulatory specificity. Additionally, it highlights financial barriers that limit patient access due to the lack of robust reimbursement mechanisms